Based on elucidated biology of ASXL1 mutations, results from SELLAS’ clinical trials in acute myeloid leukemia (AML), and reports of common occurrence of ASXL1 mutations in some solid cancers, the ...
Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay. ESR1 gene mutations are known to be linked to ...
Based on elucidated biology of ASXL1 mutations, results from SELLAS ... of revumenib (drug used in hematologic malignancies). Positive controls involved cell lines treated with staurosporine ...